Is Revlimid-dex effective in treating relapsed or refractory myeloma?
Two large clinical trials showed that Revlimid-dex is significantly more effective than high-dose dexamethasone, a standard myeloma treatment in treating relapsed or refractory myeloma. Over 700 patients throughout the world participated in these studies. Revlimid-dex significantly delayed disease progression and extended survival. Response rates were superior with Revlimid-dex as well • Patients receiving Revlimid-dex lived nearly 3 years. • Those who received Revlimid-dex right after initial remission lived longer than those who received Revlimid-dex after 2 or more therapies • Overall responses were nearly 3 times dex, with a high rate of complete responses (CR) • Patients who had a partial response (PR), complete or near complete response (CR/nCR) generally started to respond 10-11 weeks after beginning treatment. These patients continued to respond for a much longer period of time than other patients. LEARN MORE …
